問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Hematology & Oncology

Division of General Surgery

更新時間：2023-09-19

賴鴻文
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

24Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

賴鴻文

List

38Cases

2022-03-01 - 2027-08-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2023-10-02 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2015-07-31 - 2018-07-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated4Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2017-09-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated11Sites

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2023-01-31 - 2032-12-03

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2017-02-01 - 2027-02-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

2023-03-11 - 2027-03-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2025-06-01 - 2028-05-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2023-12-01 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2016-09-01 - 2020-11-09

Phase II

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY.

  • Condition/Disease

    HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

  • Test Drug

    KADCYLA

Participate Sites
10Sites

Terminated8Sites

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

曾令民
Taipei Veterans General Hospital

Division of General Surgery

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB